摘要
目的分析观察卡维地洛和美托洛尔对扩张型心肌病(DCM)心力衰竭的临床治疗效果及安全性。方法将90例DCM伴有心力衰竭的患者分为对照组和实验组两组,每组各45例。两组患者均给予常规对症支持治疗,对照组患者在上述治疗的基础之上采取美托洛尔进行治疗,实验组患者在上述治疗的基础之上采取卡维地洛进行治疗,分析观察卡维地洛、美托洛尔对DCM心力衰竭的临床疗效及安全性,并进行比较。结果卡维地洛治疗DCM心力衰竭所取得的效果优于美托洛尔,而且实验组患者所产生的不良反应显著低于对照组,P<0.05,差异具有统计学意义。结论卡维地洛是治疗DCM心力衰竭的有效药物之一,能够有效改善患者的左室功能,效果比美托洛尔要好,而且有助于改善预后,副作用也比较少。
Objective To observe the therapeutic efficacies and safeties of carvedilol and metoprolol in the treatment of dilated cardiomyopathy （DCM） with heart failure. Methods Ninety DCM patients with heart failure were divided into control group （n=45） and experimental group （n=45）. Both groups received conventional symptomatic/ supportive treatment. In addition, the control group was given metoprolol, while the experimental group was given carvedilol. The two groups were compared with respect to the therapeutic efficacies and safeties of carvedilol and metoprolol. Results Carvedilol was more effective than metoprolol in the treatment of DCM with heart failure. The experimental group showed significantly milder adverse effects than the control group （P〈0.05）. Conclusion Carvedilol, as one of the effective drugs for treating DCM with heart failure, can improve the left ventricular function, and is more effective than metoprolol in the treatment of the disease. In addition, carvedilol is helpful in improving prognosis and reducing adverse effects.
出处
《心血管病防治知识（学术版）》
2012年第5期24-25,共2页
Prevention and Treatment of Cardiovascular Disease
